The Chemours Company (CC) Q3 2024 earnings summary

Executive summary

• Net sales reached $1.5 billion in Q3 2024, up 1% year-over-year, with record TSS sales driven by 21% Opteon Refrigerants growth and higher volumes across all segments, but offset by lower prices.

• Reported net loss of $27 million, or $0.18 per diluted share, due to a $56 million non-cash goodwill impairment in APM; adjusted net income was $61 million, or $0.40 per diluted share.

• Adjusted EBITDA was $208 million, down from $211 million year-over-year, mainly due to lower pricing, but exceeded internal expectations.

• Refreshed corporate strategy, "Pathway to Thrive," introduced, targeting operational excellence, growth, portfolio management, and $250M+ in cost savings.

• The company initiated a 2024 Restructuring Program, incurring $46 million in charges in Q3 2024, with expected future run-rate cost savings of one to two times the cash costs incurred.

Financial highlights

• Q3 2024 net sales: $1.5 billion (up 1% YoY); Adjusted EBITDA: $208 million (down $3 million YoY); Adjusted Net Income: $61 million; Adjusted EPS: $0.40 (down $0.03 YoY).

• Operating cash flow was $139 million, up 6% YoY; capital expenditures were $76 million; $38 million paid in dividends.

• Gross profit for Q3: $286 million; gross margin approximately 19%.

• Price declines across all segments reduced EBITDA by $50 million, offset by $37 million in cost savings and $17 million volume gains.

• Net leverage ratio: 4.4x (trailing twelve months adjusted EBITDA); gross debt at $4.1 billion; total liquidity $1.2 billion.

Outlook and guidance

• Q4 2024 consolidated net sales expected to decline mid to high single digits sequentially; adjusted EBITDA projected to decrease in the high teens to low 20% range.

• TSS net sales to decline low teens % sequentially due to refrigerant seasonality, but Opteon Refrigerants to maintain double-digit YoY growth.

• TT and APM segments also anticipate sequential net sales and EBITDA declines, with APM EBITDA expected to remain broadly flat; macro recovery for APM expected later in 2025.

• 2025 guidance includes persistent double-digit Opteon growth, TT volume stabilization, and continued cost-out efforts; overall Adjusted EBITDA margins expected to remain around 30% or greater for TSS.

• Management expects cost savings from the 2024 Restructuring Program to be realized by end of 2025; liquidity sources expected to fund operations through at least November 2025.